Biocept Awarded Additional Patent In Japan Expanding Intellectual Property Estate To 19 Issued Patents Protecting Its Target Selector Liquid Biopsy Platform
SAN DIEGO, April 18, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has been awarded Japanese Patent No. 6081434 entitled, DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS. The issued patent covers the use of antibodies for the capture of any target of interest from any sample type on a device surface. This includes CTCs, as well as other targets of interest such as sub-cellular vesicles and exosomes that are shed by solid tumors into the blood stream. This patent is broader than previously issued patents owned by the Company, and is the nineteenth patent issued to Biocept related to its core liquid biopsy technology.
"The granting of this patent significantly expands the intellectual property protecting Biocept's CTC technology platform," said Lyle Arnold, Ph.D., Chief Scientific Officer at Biocept. "Our unique CTC and ctDNA dual platform approach allows us to provide an expanded set of biomarker content to aid physicians in making optimal treatment decisions for their cancer patients."
Michael Nall, Biocept's President and CEO, added, "This is our third patent issued in Japan, strengthening the protection of our proprietary liquid biopsy technology in an important healthcare market. Expanding our intellectual property is consistent with our strategy to leverage our patent estate by licensing our technology for global distribution and commercialization."
About Biocept
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of cancer patients, and our ability to leverage our patent estate by licensing our technology for global distribution and commercialization, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-awarded-additional-patent-in-japan-expanding-intellectual-property-estate-to-19-issued-patents-protecting-its-target-selector-liquid-biopsy-platform-300440344.html
SOURCE Biocept, Inc.
